Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199836 | 0.86 | HDAC8 (0.35) | KDM4EALDH1A1STING1HDAC8MTNR1A | |
| SCHEMBL4096845 | 0.83 | KDM4E (0.31) | KDM4EALDH1A1STING1 | |
| SCHEMBL13199715 | 0.80 | ALDH1A1 (0.39) | KDM4EALDH1A1KMT2AMTNR1AMTNR1B | |
| SCHEMBL13200370 | 0.75 | HDAC8 (0.35) | STING1NR1H3HDAC8MTNR1AMTNR1B | |
| SCHEMBL1249462 | 0.71 | STS (0.39) | ALDH1A1STING1KMT2AHDAC8GAA | |
| SCHEMBL4089798 | 0.70 | MAPT (0.38) | ALDH1A1LMNAKMT2AHDAC8EGFR | |
| SCHEMBL21060539 | 0.70 | MEN1 (0.42) | KDM4EALDH1A1LMNAKMT2AGAA | |
| SCHEMBL29562190 | 0.70 | MEN1 (0.42) | KDM4EALDH1A1LMNAKMT2AGAA | |
| SCHEMBL10982252 | 0.68 | CYP4F2 (0.50) | ALDH1A1KMT2ANR1H3MTNR1AMTNR1B | |
| SCHEMBL13303889 | 0.67 | IDO1 (0.35) | KDM4EALDH1A1STING1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1897880-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | MIF, CCL2, MSR1 | KDM4E 3212/4885ALDH1A1 134/4885STING1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.